Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer
- PMID: 9440752
- DOI: 10.1200/JCO.1998.16.1.269
Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer
Abstract
Purpose: To validate predictions of the histology (necrosis, mature teratoma, or cancer) of residual retroperitoneal masses in patients treated with chemotherapy for metastatic nonseminomatous testicular germ cell tumor.
Patients and methods: We studied 172 testicular cancer patients who underwent resection while tumor markers were normal. Predictive characteristics for the residual histology were registered, including the presence of teratoma elements in the primary tumor, the prechemotherapy level of tumor markers (alpha-fetaprotein [AFP], human chorionic gonadotropin [HCG], lactate dehydrogenase [LDH]), the size of the residual mass, and the percentage of shrinkage in mass diameter. We calculated the predicted probability of necrosis and the ratio of cancer and mature teratoma with previously published logistic regression formulas.
Results: The distribution of the residual histology was necrosis in 77 (45%), mature teratoma in 72 (42%), and cancer in 23 (13%). Necrosis could be well distinguished from other tissue, with an area under the receiver operating characteristic (ROC) curve of 82%. No tumor was found in 15 patients with a predicted probability of necrosis over 90%. The predicted probabilities corresponded reliably with the observed probabilities (goodness-of-fit tests, P > .20), although a somewhat higher probability of necrosis was observed in patients treated with chemotherapy containing etoposide. Conversely, cancer could not reliably be predicted or adequately discriminated from mature teratoma.
Conclusion: The predicted probabilities of necrosis have adequate reliability and discriminative power. These predictions may validly support the decision-making process regarding the need and extent of retroperitoneal lymph node dissection.
Similar articles
-
Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups.J Clin Oncol. 1995 May;13(5):1177-87. doi: 10.1200/JCO.1995.13.5.1177. J Clin Oncol. 1995. PMID: 7537801
-
Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor. Prediction of histology. ReHiT Study Group.Cancer. 1997 Jan 15;79(2):345-55. Cancer. 1997. PMID: 9010108
-
Retroperitoneal metastases in testicular cancer: role of CT measurements of residual masses in decision making for resection after chemotherapy.Radiology. 2000 May;215(2):437-44. doi: 10.1148/radiology.215.2.r00ma02437. Radiology. 2000. PMID: 10796922
-
Residual masses after chemotherapy for metastatic testicular cancer: the clinical implications of the association between retroperitoneal and pulmonary histology. Re-analysis of Histology in Testicular Cancer (ReHiT) Study Group.J Urol. 1997 Aug;158(2):474-8. doi: 10.1016/s0022-5347(01)64506-3. J Urol. 1997. PMID: 9224327 Review.
-
Growing teratoma syndrome.J Surg Oncol. 1994 Jan;55(1):56-60. doi: 10.1002/jso.2930550116. J Surg Oncol. 1994. PMID: 8289455 Review.
Cited by
-
[Assessment of residual tumours after systemic treatment of metastatic seminoma: ¹⁸F-2-fluoro-2-deoxy-D-glucose positron emission tomography - meta-analysis of diagnostic value].Urologe A. 2011 Mar;50(3):322-7. doi: 10.1007/s00120-010-2469-3. Urologe A. 2011. PMID: 21161157 German.
-
External validity of a prediction rule for residual mass histology in testicular cancer: an evaluation for good prognosis patients.Br J Cancer. 2003 Mar 24;88(6):843-7. doi: 10.1038/sj.bjc.6600759. Br J Cancer. 2003. PMID: 12644820 Free PMC article.
-
The role of positron emission tomography in germ cell cancer.World J Urol. 2004 Apr;22(1):41-6. doi: 10.1007/s00345-004-0403-2. Epub 2004 Mar 16. World J Urol. 2004. PMID: 15024601 Review.
-
Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes.Eur Urol Oncol. 2018 Aug;1(3):242-251. doi: 10.1016/j.euo.2018.04.005. Epub 2018 Jun 6. Eur Urol Oncol. 2018. PMID: 31058267 Free PMC article.
-
Flawed external validation study of the ADNEX model to diagnose ovarian cancer.Gynecol Oncol Rep. 2016 Sep 14;18:49-50. doi: 10.1016/j.gore.2016.09.003. eCollection 2016 Nov. Gynecol Oncol Rep. 2016. PMID: 27995172 Free PMC article. No abstract available.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical